IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

This study is a multicenter, open-label, single-arm, phase Ib/II clinical study comprising two phases: dose confirmation phase and dose expansion phase. The objective of the dose confirmation phase is to determine the recommended Phase II dose (RP2D) of IN10018+ standard chemotherapy (albumin-bound paclitaxel + gemcitabine) and IN10018 + KN046 + standard chemotherapy in subjects with advanced pancreatic cancer. The dose expansion phase will further explore the antitumor activities and safety of combination therapy in subjects with advanced pancreatic cancer.

Trial Details

NCT ID
NCT05827796
Phase
PHASE1 / PHASE2
Sponsor
InxMed (Shanghai) Co., Ltd.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • IN10018
  • Albumin-Bound Paclitaxel
  • Gemcitabine
  • KN046
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • With a full understanding of the study, each subject voluntarily agreed to participate in this study and sign the informed consent form.
  • Female or male subjects ≥ 18 years at the time of signing informed consent.
  • Histological or cytology-confirmed pancreatic ductal adenocarcinoma (including adenosquamous carcinoma).
  • No previous systemic treatment for unresectable, locally advanced, or metastatic pancreatic cancer.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →